Stockreport

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or t [Read more]